TY - JOUR
T1 - Effect of licorice on patients with HSD11B1 gene polymorphisms- a pilot study
AU - Devang, Nayana
AU - Adhikari, Prabha
AU - Nandini, M.
AU - Satyamoorthy, Kapaettu
AU - Rai, Padmalatha S.
N1 - Funding Information:
Research Society for the Study of Diabetes in India (ch#77723/3.2.11), M. Vishwanathan Diabetes Centre, Chennai and Department of Science and Technology India (DST/INSPIRE fellowship/2012/598) financially supported this study.
Funding Information:
We are greatly thankful to all the participants in this study and Manipal University for their collaboration in this study. ND is grateful to DST for funding the study.
Publisher Copyright:
© 2020 The Authors
PY - 2021/1/1
Y1 - 2021/1/1
N2 - The positive association of HSD11B1 gene polymorphism with type 2 diabetes (T2D) and prediabetic conditions has been revealed. In the current study, we assessed the effectiveness of licorice on the clinical profile of the patients with HSD11B1 gene polymorphism. Licorice (Glycyrrhiza Glabra) is a competitive inhibitor of 11 beta-hydroxysteroid dehydrogenase 1 (11β-HSD1) enzyme and has been traditionally reported as an anti-ulcer, anti-pyretic, anti-thirst, anti-inflammatory, hypoglycemic and hypolipidemic agent. The aim of the study was to assess the effectiveness of licorice on the clinical profile of participants with HSD11B1 gene polymorphism. The study was performed using diabetic patients with HSD11B1 gene polymorphism. Biochemical and anthropometric parameters were measured using standard diagnostic tools. Fourteen patients were divided into two groups by simple randomization, Licorice group (treated with 750 mg licorice/day for three weeks), and placebo group (treated with 750 mg placebo/day for three weeks). Investigations were repeated at the end of three weeks. Licorice showed a significant reduction in serum insulin levels (p = 0.03). There was no significant change in any other clinical parameters either by licorice or placebo. Conclusively, licorice moderately improves serum insulin levels in patients with HSD11B1 gene polymorphism. From our pilot study, the safety of licorice is confirmed at a dose of 750 mg/day. However, the study can be repeated at a higher dose to show its effectiveness and safety.
AB - The positive association of HSD11B1 gene polymorphism with type 2 diabetes (T2D) and prediabetic conditions has been revealed. In the current study, we assessed the effectiveness of licorice on the clinical profile of the patients with HSD11B1 gene polymorphism. Licorice (Glycyrrhiza Glabra) is a competitive inhibitor of 11 beta-hydroxysteroid dehydrogenase 1 (11β-HSD1) enzyme and has been traditionally reported as an anti-ulcer, anti-pyretic, anti-thirst, anti-inflammatory, hypoglycemic and hypolipidemic agent. The aim of the study was to assess the effectiveness of licorice on the clinical profile of participants with HSD11B1 gene polymorphism. The study was performed using diabetic patients with HSD11B1 gene polymorphism. Biochemical and anthropometric parameters were measured using standard diagnostic tools. Fourteen patients were divided into two groups by simple randomization, Licorice group (treated with 750 mg licorice/day for three weeks), and placebo group (treated with 750 mg placebo/day for three weeks). Investigations were repeated at the end of three weeks. Licorice showed a significant reduction in serum insulin levels (p = 0.03). There was no significant change in any other clinical parameters either by licorice or placebo. Conclusively, licorice moderately improves serum insulin levels in patients with HSD11B1 gene polymorphism. From our pilot study, the safety of licorice is confirmed at a dose of 750 mg/day. However, the study can be repeated at a higher dose to show its effectiveness and safety.
UR - http://www.scopus.com/inward/record.url?scp=85089397426&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089397426&partnerID=8YFLogxK
U2 - 10.1016/j.jaim.2020.06.006
DO - 10.1016/j.jaim.2020.06.006
M3 - Article
AN - SCOPUS:85089397426
SN - 0975-9476
VL - 12
SP - 131
EP - 135
JO - Journal of Ayurveda and Integrative Medicine
JF - Journal of Ayurveda and Integrative Medicine
IS - 1
ER -
